156 related articles for article (PubMed ID: 2257203)
1. Dacarbazine (DTIC) and human recombinant interferon alpha 2a (Roferon) in the treatment of disseminated malignant melanoma.
Mulder NH; Willemse PH; Schraffordt Koops H; de Vries EG; Sleijfer DT
Br J Cancer; 1990 Dec; 62(6):1006-7. PubMed ID: 2257203
[No Abstract] [Full Text] [Related]
2. Dacarbazine (DTIC), human recombinant interferon alpha 2a (Roferon) and 5-fluorouracil for disseminated malignant melanoma.
Mulder NH; de Vries EG; Sleijfer DT; Schraffordt Koops H; Willemse PH
Br J Cancer; 1992 Feb; 65(2):303-4. PubMed ID: 1739635
[No Abstract] [Full Text] [Related]
3. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma.
Bajetta E; Di Leo A; Zampino MG; Sertoli MR; Comella G; Barduagni M; Giannotti B; Queirolo P; Tribbia G; Bernengo MG
J Clin Oncol; 1994 Apr; 12(4):806-11. PubMed ID: 8151323
[TBL] [Abstract][Full Text] [Related]
4. Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma.
Falkson CI
Med Oncol; 1995 Mar; 12(1):35-40. PubMed ID: 8542245
[TBL] [Abstract][Full Text] [Related]
5. Recombinant interferon alpha-2a in combination with dacarbazine in the treatment of metastatic malignant melanoma: analysis of long-term responding patients.
Ron IG; Inbar MJ; Gutman M; Merimsky O; Chaitchik S
Cancer Immunol Immunother; 1993 Jul; 37(1):61-6. PubMed ID: 8513453
[TBL] [Abstract][Full Text] [Related]
6. Interferon alpha-2a and dacarbazine in melanoma.
Kirkwood JM; Ernstoff MS; Giuliano A; Gams R; Robinson WA; Costanzi J; Pouillart P; Speyer J; Grimm M; Spiegel R
J Natl Cancer Inst; 1990 Jun; 82(12):1062-3. PubMed ID: 2189999
[No Abstract] [Full Text] [Related]
7. Phase II study of interferon alpha-2a and dacarbazine in advanced melanoma.
Bajetta E; Negretti E; Giannotti B; Brogelli L; Brunetti I; Sertoli MR; Bernengo MG; Sofra MC; Maifredi G; Zumiani G
Am J Clin Oncol; 1990 Oct; 13(5):405-9. PubMed ID: 2220660
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma.
Vuoristo MS; Hahka-Kemppinen M; Parvinen LM; Pyrhönen S; Seppä H; Korpela M; Kellokumpu-Lehtinen P
Melanoma Res; 2005 Aug; 15(4):291-6. PubMed ID: 16034308
[TBL] [Abstract][Full Text] [Related]
9. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
10. Fotemustine and dacarbazine plus recombinant interferon alpha 2a in thetreatment of advanced melanoma.
Comella P; Daponte A; Casaretti R; Ionna F; Fiore F; Presutti F; Frasci G; Caponigro F; Gravina A; Parziale AP; Mozzillo N; Comella G
Eur J Cancer; 1997 Jul; 33(8):1326-9. PubMed ID: 9301463
[TBL] [Abstract][Full Text] [Related]
11. Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma.
Mulder NH; van der Graaf WT; Willemse PH; Koops HS; de Vries EG; Sleijfer DT
Br J Cancer; 1994 Oct; 70(4):681-3. PubMed ID: 7522510
[TBL] [Abstract][Full Text] [Related]
12. Effects of interferon-alpha, verapamil and dacarbazine in the treatment of advanced malignant melanoma.
Andersson R; Ake Hofer P; Riklund-Ahlström K; Henriksson R
Melanoma Res; 2003 Feb; 13(1):87-91. PubMed ID: 12569290
[TBL] [Abstract][Full Text] [Related]
13. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma.
Maio M; Mackiewicz A; Testori A; Trefzer U; Ferraresi V; Jassem J; Garbe C; Lesimple T; Guillot B; Gascon P; Gilde K; Camerini R; Cognetti F;
J Clin Oncol; 2010 Apr; 28(10):1780-7. PubMed ID: 20194853
[TBL] [Abstract][Full Text] [Related]
14. Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma.
Middleton M; Hauschild A; Thomson D; Anderson R; Burdette-Radoux S; Gehlsen K; Hellstrand K; Naredi P
Ann Oncol; 2007 Oct; 18(10):1691-7. PubMed ID: 17709802
[TBL] [Abstract][Full Text] [Related]
15. Treatment of advanced malignant melanoma with recombinant interferon alfa-2a in combination with DTIC: long-term follow-up of two phase II studies.
Hersey P; McLeod GR; Thomson DB
Br J Haematol; 1991 Oct; 79 Suppl 1():60-6. PubMed ID: 1931712
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of interferons in malignant melanoma.
McLeod GR; Thomson DB; Hersey P
J Invest Dermatol; 1990 Dec; 95(6 Suppl):185S-187S. PubMed ID: 1701806
[TBL] [Abstract][Full Text] [Related]
17. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial.
Thomson DB; Adena M; McLeod GR; Hersey P; Gill PG; Coates AS; Olver IN; Kefford RF; Lowenthal RM; Beadle GF
Melanoma Res; 1993 Apr; 3(2):133-8. PubMed ID: 8518552
[TBL] [Abstract][Full Text] [Related]
18. Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma.
Falkson CI; Falkson G; Falkson HC
J Clin Oncol; 1991 Aug; 9(8):1403-8. PubMed ID: 2072144
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of combined administration of dacarbazine and carboplatin with home therapy of recombinant interleukin-2 and interferon-alpha 2a in patients with advanced malignant melanoma.
Ron IG; Mordish Y; Eisenthal A; Skornick Y; Inbar MJ; Chaitchik S
Cancer Immunol Immunother; 1994 Jun; 38(6):379-84. PubMed ID: 8205559
[TBL] [Abstract][Full Text] [Related]
20. Dose escalation of dacarbazine combined with interferon alpha-2a, G-CSF and ondansetron in patients with metastatic melanoma.
Buter J; Sleijfer DT; Willemse PH; van der Graaf WT; de Vries EG; Schraffordt Koops H; Mulder NH
Anticancer Res; 1994; 14(3B):1325-8. PubMed ID: 7520681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
